Celcuity Inc.

Sru Biosystems, Inc.

X-body, Inc.

Anadys Pharmaceuticals, Inc.

Anadys Pharmaceutical, Inc.

Lance Gavin Laing

Gangadhar Jogikalmath

Timothy Smith

Brian Francis Sullivan

Peter Li

Rafael Fernandez

Rick Wagner

Brian T Cunningham

Bo Lin

Christine C Genick

Lara Madison

Brant Binder

Sharon T Cload

Stephen C Schulz

Jaime E Arenas

William C Karl

Andrew A Pakula

James W Lillie

Alex Borsody

Alexander Yuzhakov

John Gerstenmeier, Iii

Ben Rich

Abhijit Dandapat

John Gerstenmaier, Iii

Kurt Albertson

Guo Bin Wang

Cheryl L Baird

Provided are methods of treating cancer in a human subject. The method includes selecting a subject in need of treatment of cancer; administering to the subject a therapeutically effective amount of gedatolisib at least once a week for a period of three weeks; discontinuing administration of gedatolisib for a period of one week; and resuming administration of gedatolisib at least once a week following the period of discontinuation. The administration for at least a period of three weeks and discontinued administration for at least a period of one week constitutes a cycle, where the cycle is repeated for at least two cycles.

Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea

Provided herein are methods for simultaneously determining the functional status of multiple signaling pathways in a diseased cell sample obtained from a subject to thereby select for therapeutic use in the subject a targeted therapeutic agent that affects the signaling pathway with the highest level of aberrant activity in the subject's cells. Also provided are methods for determining whether a signaling pathway is ultrasensitive in a diseased cell sample from a subject, also allowing for selection of an effective targeted therapeutic agent for therapeutic use in the subject. Methods of administering a selected targeted therapeutic agent to the subject are also provided.

Methods of measuring signaling pathway activity for selection of therapeutic agents

The invention provides methods of preparing a sample of viable diseased cells obtained from a human subject for clinical testing, wherein the methods inhibit anoikis and/or anoikis in the cells while maintaining the physiological functions and genomic composition of the cells when they were in vivo. In the methods of the invention, primary cells are cultured in media comprising at least one anoikis inhibitor, preferably at least one inhibitor of an intrinsic anoikis pathway and at least one inhibitor of an extrinsic anoikis pathway, under anti-anoikis atmospheric conditions, such as greater than 2% and less than 20% oxygen. Method combining multiple culturing conditions, including surface attachment under conditions that inhibit anoikis, are also provided. Compositions and kits for use in the methods of the invention are also provided.

Methods of preparing a primary cell sample

Provided herein are methods for determining the functional status of a cellular pathway in a diseased cell sample obtained from an individual subject. These methods involve contacting a diseased cell sample obtained from the subject with a perturbing agent (e.g., an activating agent) known to perturb a specific cellular pathway when the pathway is functioning normally. A change in one or more physiological response parameters in the presence of the perturbing agent indicates that the cellular pathway targeted by the perturbing agent is functional in the individual subject. Methods of selecting a targeted therapeutic agent for an individual subject are also provided.

Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent

The invention provides methods for identifying modulators of ion channels without the use of recombinant cell lines over-expressing the ion channel proteins or the use of detection labels.

Methods for identifying modulators of ion channels

The disclosure provides methods for analysis of disease cell response to a therapeutic agent. In embodiments, a method comprises administering the therapeutic agent to a disease cell sample from the subject in a device that measures at least one physiological parameter of a cell; determining whether a change occurs in the physiologic parameter of the disease cell sample in response to the therapeutic agent as compared to a baseline measurement or the physiological parameter before administration of the therapeutic agent, and selecting the therapeutic agent that results in the change in the at least one physiologic parameter. In embodiments, the disease cells are whole, viable, and/or label free.

Whole cell assays and methods

Method for determining ion channel modulating properties of a test reagent

The invention provides methods of detecting a change in cell growth patterns, methods of screening many different antibodies in one receptacle, and methods of detecting specific binding of an antibody to a protein or cell, wherein the antibody is in a mixture of many different antibodies.

Methods for screening cells and antibodies

The invention provides methods of detecting a change in cell growth patterns.

High resolution label free analysis of cellular properties

Methods are provided to detect changes in cells without the use of detection labels.

Methods of detection of changes in cells

Growing community of inventors

Belmont, MA, United States of America

Lance Gavin Laing